Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that George Kemble, PhD will serve as a Senior Scientific Advisor. Dr. Kemble is a veteran biotech executive and scientist with a specialty focus in the areas of virology, vaccines and small molecule biologics. Dr. Kemble is currently the Chairman of the Board at Sagimet Bioscience ...

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]

SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical ...

Group 1 - The article discusses Sagimet Biosciences Inc. (SGMT) and highlights positive data from a China partner regarding Acne Vulgaris, which is expected to bode well for the company's product TVB-3567 [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not contain any stock or derivative positions in the companies mentioned, nor does it plan to initiate any such positions in the near future [3] - Seeking Alpha emphasizes that past performance is not indicative of future results and does not provide specific investment recommendations [4]

Core Insights - Sagimet Biosciences Inc. announced positive results from the Phase 1 pharmacokinetic trial of its combination therapy involving denifanstat and resmetirom, targeting metabolic dysfunction-associated steatohepatitis (MASH) [1][4] Group 1: Trial Details - The Phase 1 PK trial was an open-label, 2-cohort study with 40 healthy adult participants, aimed at evaluating pharmacokinetics, potential drug-drug interactions, and safety [2] - The combination of denifanstat and resmetirom was well-tolerated, with no serious adverse events or clinically significant laboratory results reported [3][7] Group 2: Future Development Plans - Sagimet plans to advance the combination therapy into a Phase 2 proof-of-concept efficacy trial for patients with MASH and F4 fibrosis, pending regulatory consultation [4][5] - The company aims to initiate the Phase 2 study in the second half of 2026, leveraging data from the Phase 1 trial [5][7] Group 3: Product Information - Denifanstat is an oral, once-daily selective FASN inhibitor, while resmetirom is commercially available as Rezdiffra for non-cirrhotic MASH with moderate to advanced fibrosis [5][6] - Preclinical data indicated a synergistic effect of the combination on liver disease markers, showing improved NAS and hepatic collagen content compared to single agents [5][6] Group 4: Market Context - MASH is a severe liver disease affecting over 265 million people globally, characterized by fat accumulation in the liver and associated metabolic changes [8] - There are currently no approved treatments for MASH cirrhosis (F4), highlighting a significant unmet medical need [8]

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical developmentSagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagimet anticipates selecting one of the innovative forms of resmeti ...

Core Insights - Sagimet Biosciences Inc. has granted an exclusive license for denifanstat to Ascletis Pharma Inc. for the treatment of moderate to severe acne in China, following the acceptance of its New Drug Application (NDA) by China's National Medical Products Administration (NMPA) [1][2] - Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor, which has shown positive results in clinical trials for both acne and metabolic dysfunction associated steatohepatitis (MASH) [2][3] Company Overview - Sagimet Biosciences is focused on developing novel FASN inhibitors aimed at addressing dysfunctional metabolic and fibrotic pathways, particularly those linked to the overproduction of palmitate [3] - The company has successfully completed Phase 2b clinical trials for denifanstat in MASH and has partnered with Ascletis for its Phase 3 clinical trials in moderate-to-severe acne, where denifanstat met all primary and secondary endpoints [3] Clinical Development - Denifanstat has been well tolerated in clinical trials, with Ascletis' Phase 3 trial demonstrating success in treating moderate to severe acne vulgaris [2] - Sagimet is also testing a combination of denifanstat and resmetirom in a Phase 1 PK clinical trial, targeting cirrhotic patients with F4-stage MASH, and is developing a second oral FASN inhibitor, TVB-3567, which is currently in Phase 1 trials [3]

Core Insights - Sagimet Biosciences Inc. announced the approval of inducement grants of 42,800 stock options to three newly-hired employees as part of their employment compensation [1][2] - The stock options will have an exercise price based on the closing price of Sagimet's Series A common stock on December 9, 2025, and will vest over a four-year period [3] Company Overview - Sagimet is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors to address dysfunctional metabolic and fibrotic pathways, particularly related to the overproduction of palmitate [4] - The company’s lead product, denifanstat, has shown positive results in clinical trials for metabolic dysfunction associated steatohepatitis (MASH) and is also being tested in combination with resmetirom for cirrhotic patients with F4-stage MASH [4] - Another product, TVB-3567, is currently undergoing a Phase 1 first-in-human clinical trial for acne treatment [4]

Summary of Sagimet Biosciences FY Conference Call Company Overview - **Company**: Sagimet Biosciences (NasdaqGM:SGMT) - **Focus**: Development of novel therapeutics targeting fatty acid synthesis for diseases such as MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) and acne [1][2] Key Points on MASH Program - **Lead Molecule**: Denifenstat, a potent FASN (fatty acid synthase) inhibitor, is being developed for MASH and acne [2][3] - **Mechanism of Action**: Denifenstat targets fat, inflammation, and fibrosis, differentiating it from other treatments that primarily focus on fat oxidation or mobilization [3][10] - **Clinical Data**: - Phase IIB study showed a 30% placebo-adjusted improvement in fibrosis [10] - In F4 patients, 11 out of 13 showed a one or two-stage improvement in fibrosis [6][4] - **Combination Therapy**: A combination program with resmetirom is underway, showing enhanced effects on inflammation and fibrosis [6][18] - **Funding Needs**: Approximately $400 million is required to complete the Phase III study for the F2 and F3 populations, with current cash reserves at $125 million [16][30] Key Points on Acne Program - **Partnership**: Collaboration with Ascletis in China for acne studies, showing 20% placebo-adjusted improvements in lesion reduction [8][23] - **Regulatory Pathway**: Plans to seek FDA guidance in early 2026 regarding the use of Ascletis' Phase III data for U.S. regulatory approval [24][25] - **Next-Gen Molecule**: Development of TVB-3567, a more potent follow-on oral FASN product, is in Phase I [25][26] - **Market Potential**: The acne market is significant, with an estimated 50 million Americans affected, and the introduction of effective treatments is expected to increase patient demand [23][24] Financial Considerations - **Royalty Stream**: Expected inflow of approximately $120 million from milestones and royalties related to the acne program in China [29] - **Capitalization Requirements**: The company acknowledges the need for substantial funding to support ongoing and future clinical programs [30] Additional Insights - **Unique Positioning**: Denifenstat is the only FASN inhibitor in development, which is a significant differentiator in the market [11][12] - **Long-Term Strategy**: The company recognizes the necessity for combination therapies in treating patients effectively, indicating a strategic approach to drug development [20][21] - **Intellectual Property**: New IP filed for the combination therapy is expected to provide protection until 2044 [22] This summary encapsulates the critical insights from the Sagimet Biosciences FY conference call, highlighting the company's strategic direction, clinical advancements, and financial outlook.

Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [1][3] Company Overview - Sagimet is developing FASN inhibitors aimed at conditions caused by the overproduction of the fatty acid palmitate [3] - Denifanstat, an oral medication, has successfully met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial for MASH and in a Phase 3 clinical trial for moderate-to-severe acne in partnership with a licensee in China [3] - A combination therapy of denifanstat and resmetirom is currently undergoing a Phase 1 PK clinical trial, with plans for development in cirrhotic patients with F4-stage MASH [3] - TVB-3567, another oral FASN inhibitor, is in a Phase 1 first-in-human clinical trial for acne [3] Upcoming Events - Management will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, with a fireside chat scheduled for 12:55 PM ET [1] - A webcast of the event will be available on Sagimet's website, with an archived replay accessible for 90 days post-event [2]